Jeff Jones
Stock Analyst at Oppenheimer
(3.01)
# 1,257
Out of 5,179 analysts
92
Total ratings
25.3%
Success rate
6.44%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Outperform | $60 → $62 | $22.49 | +175.68% | 4 | Mar 20, 2026 | |
| PHAR Pharming Group | Reiterates: Outperform | $42 → $41 | $16.31 | +151.38% | 1 | Mar 13, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $32 → $33 | $14.01 | +135.55% | 7 | Mar 13, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $53 → $57 | $8.71 | +554.42% | 11 | Mar 10, 2026 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $44 → $50 | $21.46 | +132.99% | 4 | Mar 6, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $78.16 | +53.53% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.46 | +1,612.33% | 9 | Aug 27, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $24.80 | +0.81% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $5.93 | +186.68% | 4 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $29.44 | +192.12% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $2.21 | +714.48% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.70 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $4.07 | +293.12% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.17 | +3,746.15% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.00 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $3.66 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.75 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.31 | +1,045.04% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $2.44 | +76,744.26% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $3.52 | +31,150.00% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $60 → $62
Current: $22.49
Upside: +175.68%
Pharming Group
Mar 13, 2026
Reiterates: Outperform
Price Target: $42 → $41
Current: $16.31
Upside: +151.38%
Corvus Pharmaceuticals
Mar 13, 2026
Reiterates: Outperform
Price Target: $32 → $33
Current: $14.01
Upside: +135.55%
Corbus Pharmaceuticals Holdings
Mar 10, 2026
Maintains: Outperform
Price Target: $53 → $57
Current: $8.71
Upside: +554.42%
ArriVent BioPharma
Mar 6, 2026
Reiterates: Outperform
Price Target: $44 → $50
Current: $21.46
Upside: +132.99%
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $78.16
Upside: +53.53%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.46
Upside: +1,612.33%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $24.80
Upside: +0.81%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $5.93
Upside: +186.68%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $29.44
Upside: +192.12%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $2.21
Upside: +714.48%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.70
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $4.07
Upside: +293.12%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.17
Upside: +3,746.15%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $9.00
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $3.66
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.75
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.31
Upside: +1,045.04%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $2.44
Upside: +76,744.26%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $3.52
Upside: +31,150.00%